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This data article contains data from a multidisciplinary ques-
tionnaires filled in by 178 expert physicians on the usage of non-
vitamin K Oral Anticoagulants in patients with atrial fibrillation (AF)
and for the treatment of patients with venous thromboembolism
(VTE). The questionnaire consists of 9 statements of clinical complex
AF and VTE cases and informative campaign on antithrombotic
therapy for stroke prevention in AF. The data are potentially valuable
for the scientific community, showing the doubts of different spe-
cialists (Internists, Pneumologists, Geriatricians, Cardiologists and
Neurologists) with a large experience in prescribing oral antic-
oagulation in difficult AF and VTE cases (see full list of participants
provided). The data obtained in some particular clinical cases such as
CHA2DS2-VASc¼1, comorbid coronary artery disease, frailty,
advanced age, risk of falling and prior haemorrhagic stroke, can be
compared with indications from published guidelines and recom-
mendations for future insight and to be considered as a benchmark
for future trials in the area or oral anticoagulation for AF and VTE.ier Inc. This is an open access article under the CC BY license
/j.ijcard.2017.09.159
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P. Colonna et al. / Data in Brief 15 (2017) 532–539 533The data concerning informative campaign on antithrombotic
therapy for stroke prevention showed the expert panel agreement
on the inclusion of self monitoring of heart rhythm by pulse taking
in subjects older than 64 years of age (81% agreement, item 3);
knowledge that the risk of stroke associated with AF is almost twice
the risk associated with hypertension (95% agreement, item 4);
knowledge that the CHA2DS2-VASc score exerts a higher influence
on stroke risk compared to AF duration (92% agreement, item 5);
knowledge that stroke prevention in AF with a NOAC is more
effective, does not cause any higher bleeding risk, and is equally
simple compared to aspirin treatment (91% agreement, item 6).
Data on strategies to optimise appropriate prescription of
antithrombotic therapy showed agreement on the utility of short
television advertisements about the risks of stroke associated with
AF (79% agreement, item 8), on a campaign encouraging regular
control of cardiac rhythm by pulse taking (77% agreement, item 1),
on a campaign reporting the advantages of anticoagulation over no
antithrombotic therapy (98% agreement, item 2) or of NOACs over
aspirin (96% agreement, item 3) or on the practical use of NOAC (93%
agreement, item 6) or on stroke and bleeding risk scores (87%
agreement, item 7). See Colonna et al. (2017) [1] for further inter-
pretation and discussion.
& 2017 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Medicine
ore specific subject
areaUse of anticoagulants in difficult cases of AF and VTEype of data Tables, text file, list of expert, graph, figure
ow data was acquired Large (178 expert physicians) multidisciplinary survey; subsequent analysis
according to the Delphi methodology
ata format Analyzed and grouped
xperimental factors Nine challenging cases of patients with atrial fibrillation and venous
thromboembolism
xperimental features Nine separate cases, each of them with multiple statements with 5 level of
agreement to be voted by the panel of 178 expert physicians. Following
analysis of concordance, according to Delphi technique.ata source location More than 150 different Italian cities where the surveys were filled in
ata accessibility All the data are supplied in this articleValue of the data:
 Complete data derived from 178 questionnaires filled in by Italian AF and VTE expert physicians,
consisting of 9 statements of clinical complex AF and VTE cases and informative campaign on
antithrombotic therapy for stroke prevention in AF.
 Data potentially valuable for the scientific community, showing the doubts of different specialists
(Internists, Pneumologists, Geriatricians, Cardiologists and Neurologists) with a large experience in
prescribing oral anticoagulation in difficult AF and VTE cases (see full list of participants provided).
 The data obtained in some particular clinical cases such as CHA2DS2-VASc¼1, comorbid coronary
artery disease, frailty, advanced age, risk of falling and prior haemorrhagic stroke, can be compared
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considered as a benchmark for future trials in the area or oral anticoagulation for AF and VTE.
 The innovative data on criteria for an informative campaign on antithrombotic therapy for stroke
prevention and on strategies to optimise appropriate prescription of antithrombotic therapy helps
to possible new collaborations for further studies.1. Data
New unreported data concerning informative campaign on antithrombotic therapy for stroke
prevention (See “Statement 8” Table and Fig. 1H) showed the expert panel agreement on the inclusion
of: self monitoring of heart rhythm by pulse taking in subjects older than 64 years of age (81%
agreement, item 3); knowledge that the risk of stroke associated with AF is almost twice the risk
associated with hypertension (95% agreement, item 4); knowledge that the CHA2DS2-VASc score
exerts a higher influence on stroke risk compared to AF duration (92% agreement, item 5); knowledge
that stroke prevention in AF with a NOAC is more effective, does not cause any higher bleeding risk,
and is equally simple compared to aspirin treatment (91% agreement, item 6). The panel also agreed
that cardioembolic stroke risk is not reduced after cardioversion from AF to sinus rhythm (81%
agreement, item 1) (Ref. [2]) and that inappropriate NOAC dose reduction may reduce the efficacy in
preventing thromboembolic stroke compared to the full dose regimen (97% agreement, item 2)
Data in the second Supplementary statement (see “Statement 9” Table and Fig. 1I) showed the
indications of expert physicians on strategies to optimise appropriate prescription of antithrombotic
therapy. The panel agreed on the utility of short television advertisements about the risks of stroke
associated with AF (79% agreement, item 8), on a campaign encouraging regular control of cardiac
rhythm by pulse taking (77% agreement, item 1), on a campaign reporting the advantages of antic-
oagulation over no antithrombotic therapy (98% agreement, item 2) or of NOACs over aspirin (96%
agreement, item 3) or on the practical use of NOAC (93% agreement, item 6) or on stroke and bleeding
risk scores (87% agreement, item 7). Additionally, the panel agreed on the benefits of abolishing the
mandatory electronic form for NOAC prescription, restricting the use to a selected group representing
a minority of guideline-eligible patients (80% agreement, item 4), while it did not reach consensus on
the possibility that every physician may be allowed to prescribe a NOAC (51% ND/49% NA, item 5).2. Experimental design, materials and methods
The experimental design to collect the present data is derived by the Delphi method, characterized
by a large number of participants without the need for face-to-face contacts (Ref. [3]), the only choice
when therapeutic decisions routine clinical practice are challenging because of lack of evidence from
clinical trials in selected groups of patients, such as those with high risk of bleeding, multiple
comorbidities, or receiving potentially interfering drugs.
The materials and methods consists of a Delphi Consensus panel organized to address multiple
unanswered questions related to the clinical management of difficult cases of patients with AF or VTE.
We used a modified Delphi method (Refs. [4,5]) to reach consensus in a voting panel of 178
medical doctors from different specializations (Internists, Pneumologists, Geriatricians, Cardiologists
and Neurologists) with a large experience in prescribing oral anticoagulation (Ref [6]) for AF or VTE
(see full list of participants included in the Appendix A of the present Data in Brief).
The following list of 9 statements on controversial topics in AF and VTE antithrombotic man-
agement was selected for the Delphi panel: 1- AF in a recent acute coronary syndrome-drug eluting
stent (ACS-DES) patient at moderate-high bleeding risk; 2- Recurrent AF in an elderly patient with
impaired renal function; 3- A challenging CHA2DS2 VASc (congestive heart failure, hypertension, age
Fig. 1. Summary of results for all statements. Distribution of the panel’s answers on the nine statements. Y-axis ¼ percentage
of panel votes; X-axis ¼ items listed in each statement (see Ref. [1] for full explanation). ND: neither disagree; NA: nor agree.
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Table 1
AF in recent ACS-DES at moderate-high bleeding risk. Flow chart of the panel’s scores on the four listed items. Treatment with
aspirin and a NOAC, according to the SmPC, is considered the most appropriate option (84%). Low NOAC dose, regardless of
SmPC indications, divides the panel, with lack of consensus (44% vs 56%). The experts unanimously do not consider NOAC
discontinuation (98%) or NOAC replacement with warfarin (86%) appropriate options. ACS: acute coronary syndromes; DES:
drug eluting stenting; ND: neither disagree; NA: nor agree.
P. Colonna et al. / Data in Brief 15 (2017) 532–539536Z75, diabetes, prior stroke, vascular disease, age 65–74, sex category) ¼1 case; 4- AF with prior
hypertension-associated haemorrhagic stroke; 5- AF in a patient at high risk of falling; 6- Hemody-
namically stable patient with pulmonary embolism; 7- Moderate risk pulmonary embolism in a frail
lady; 8- Need for an informative AF campaign; 9- Potential hurdles to guideline-based antithrombotic
therapy for AF.
Each statement was declined in 4 or more items, and each of the 178 expert physicians freely,
individually, and anonymously delivered his/her level of agreement according to the following
5-point Likert scale: 1 ¼ absolutely disagree, 2 ¼ disagree, 3 ¼ agree, 4 ¼ more than agree, 5 ¼
absolutely agree. Consensus was reached when the sum of items 1 and 2 (Disagree) or 3, 4 and 5
(Agree) reached 66%. Where no consensus was reached the data were shown as Neither Disagree/Nor
Agree (ND/NA), with ND standing for the sum of items 1 and 2 and NA as the sum of items 3, 4 and 5.
Then, the experts participated in a plenary session held in Mestre, Italy, on October 5th 2016,
where the data were presented and discussed. Agreement was reached on most – but not all – items.
In case of no agreement, a second round of voting was purposely not performed in order to highlight
the inconsistencies of opinion or the insufficient information of evidence-based literature on the
therapeutic options for certain AF/VTE patients.
The Tables and the figure with the graphs from all statements are supplied to fully understand the
data (Tables 1-5). See Ref. [1] for further interpretation and discussion.
Table 3
AF in prior hypertension-associated haemorrhagic stroke. Flow chart of the panel’s scores. The panel disagrees with ruling out
antithrombotic therapy entirely (92%), but excludes aspirin (97%) or warfarin (84%). The panel agrees with NOAC therapy,
according to the SmPC (89%), but is divided on using a low dose NOAC (52% vs 48%) or on LAA closure without any antic-
oagulation (39% vs 61%). LAA: left atrial appendage; ND: neither disagree; NA: nor agree.
Table 2
Challenging CHA42DS2-VASc¼1. Flow chart of the panel’s scores. Four of the five therapeutic options do not reach consent. The
panel unanimously disagrees with warfarin as an option (96%). ND: neither disagree; NA: nor agree.
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Table 5
Moderate risk pulmonary embolism in a little, old, frail lady. Flow chart of the panel’s scores. The panel disagrees with pre-
scribing a NOAC at full dose, either with parenteral treatment (74%) or after a loading dose (69%). It does not reach a consensus
on prescribing parenteral therapy followed by low-dose NOAC (35% vs 65%), or parenteral therapy together with warfarin (41%
vs 59%), or direct NOAC loading dose with subsequent dose reduction (44% vs 56%). ND: neither disagree; NA: nor agree. See
Ref. [1] for further interpretation and discussion.
Table 4
AF in an old patient at high risk of falling. Flow chart of the panel’s scores. The panel disagrees with considering the risk of
falling a contraindication to antithrombotic treatment (94%). It also disagrees with aspirin (98%) or warfarin (66%) as treatment
options, preferring the use of a NOAC, according to the SmPC (86%). NOAC dose reduction, regardless of SmPC indications, does
not reach a consensus (54% vs 46%). ND: neither disagree; NA: nor agree.
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